ATROPINE SULFATE

5mg to a maximum of 3mg. Paediatric population Not recommended. Elderly As for Adults.

Method of administration:

Atropine 1mg in 5ml is administered by intravenous injection.

The most commonly reported adverse events are due to the action of atropine on muscarinic and, at high doses, on nicotinic receptors. These effects are dose-related and usually reversible when therapy is discontinued.

Immune system disorders:

Anaphylaxis Psychiatric disorders: Nervousness, confusional state, especially in the elder1y. At higher doses hallucinations, restlessness, and delirium.

Eye disorders:

Dilatation of the pupils with loss of accommodation and photophobia, decrease in lachrymal secretion, increase in intraocular pressure.

Cardiac disorders:

Tachycardia, palpitations, arrhythmias. Vascular.

Flushing Respiratory, thoracic and mediastinal disorders:

Thickening of bronchial secretions.

Gastrointestinal disorders:

Dry mouth, nausea, vomiting, and constipation.

Renal and urinary disorders:

Urinary retention.

Skin and subcutaneous tissue:

Dry skin General: Thirst Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

uk/yellowcard.

Use with caution in case of:

Prostatic enlargement Renal or hepatic insufficiency Cardiac insufficiency, arrhythmias, hyperthyroidism Chronic obstructive pulrnonary disease, as a reduction in bronchial secretions may lead to the formation of bronchial plugs Paralytic ileus, intestinal atonia in elderly, toxic megacolon Pyloric stenosis Fever, or when ambient temperature is high In the elderly, who are more susceptible to adverse effects.

.

6). o Achalasia of the oesophagus